C2N files FDA submission for Alzheimer’s blood-test

C2N Diagnostics has submitted a regulatory filing to the U.S. Food and Drug Administration for its Alzheimer’s disease blood test, a milestone the firm calls a first in the field of medicine. The test combines high-resolution mass spectrometry to measure multiple plasma β-amyloid and tau peptide iso…